← Back to Search

Inhibitor of Apoptosis Protein (IAP) antagonist

APG-1387 for Injection for Cancer

Phase 1
Waitlist Available
Research Sponsored by Ascentage Pharma Group Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18-24 months
Awards & highlights

Study Summary

This trial is testing the effects of a new drug, APG-1387, on patients with advanced solid tumors or lymphomas. So far, the drug has been well-tolerated in the patients tested. The goal of the trial is to further assess the antitumor effects of APG-1387 in combination with either pembrolizumab or a chemotherapeutic agent.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18-24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18-24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD)
Secondary outcome measures
Anti-tumor effects of APG-1387 as a single agent
Anti-tumor effects of APG-1387 in combination with pembrolizumab or combination with paclitaxel and carboplatin in patients with advanced solid tumors
Pharmacokinetic evaluation
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: APG-1387 for InjectionExperimental Treatment1 Intervention
APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
APG-1387
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Ascentage Pharma Group Inc.Lead Sponsor
49 Previous Clinical Trials
5,052 Total Patients Enrolled
Yifan Zhai, MD, PhDStudy ChairAscentage Pharma Group Inc.
18 Previous Clinical Trials
1,223 Total Patients Enrolled
~12 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top